PubMed1990
The therapeutic effect of long-term enalapril administration was studied in 20 patients with severe essential hypertension (EH), resistant to intensive therapy with a combination of 3 or 4 antihypertensive drugs. Addition of enalapril (Renitec MSD from 5 to 40 mg/day) to the previous therapy allowed to maintain blood pressure within limits not exceeding 150/95 mmHg during a 12-month study in more than 80% of previously resistant patients. Left ventricular hypertrophy regressed in all patients and dilatation of the left ventricle seen in 4 patients disappeared during enalapril treatment. Serum sodium creatinine did not change significantly. Serum potassium increased slightly but remained within the normal range. Proteinuria had a tendency to diminish and N-acetyl-beta-D-glucosaminidase activity in the urine dropped within normal limits. Based on their results, the authors conclude that enalapril is suitable for the long-term treatment of patients with severe EH, resistant to intensive antihypertensive therapy, with minimal side effects, good tolerance and a tendency for amelioration of cardiac and renal function.
Adrenergic beta-Antagonists↗